1.50Open1.50Pre Close0 Volume8 Open Interest17.50Strike Price0.00Turnover673.83%IV314.85%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry1.50Extrinsic Value100Contract SizeAmericanOptions Type0.5213Delta0.0515Gamma3.05Leverage Ratio-0.0681Theta0.0006Rho1.59Eff Leverage0.0046Vega
Nevro Stock Discussion
6 mins ago
Nevro's Hfx Iq™ Spinal Cord Stimulation With AI Technology Receives Ce Mark Certification in Europe, Increasing Product Expansion Globally
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
Nevro Corp. (NYSE: NVRO) has announced the FDA approval and market release of HFX iQ™ with HFX AdaptivAI™, an AI-driven spinal cord stimulation (SCS) system for chronic pain management. This technology leverages insights from over 100,000 patients and more than 100 million data points to provide personalized, responsive pain relief in real time.
Key features of HFX Adaptiv...
News:
• $PyroGenesis Canada (PYR.US)$ +5.9% (announces that the negotiation for the land-based system to destroy PFAS contract has been suspended and discontinued)
• $Immatics (IMTX.US)$ +3.1% (announces a clinical data update for the IMA203)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +1.6% (rising with softness in futures)
• $Nevro (NVRO.US)$ +1.4% (comments on $UnitedHealth (UNH.US)$ medical coverage policy u...
No comment yet